[Penicillamine-induced polymyositis (author's transl)].
D000368:Aged; D000906:Antibodies / Q000032:analysis; D000974:Antibodies, Antinuclear / Q000032:analysis; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology; D001327:Autoimmune Diseases / Q000139:chemically induced; D003094:Collagen / Q000276:immunology; D003348:Cortisone / Q000009:adverse effects / Q000627:therapeutic use; D003480:Cushing Syndrome / Q000139:chemically induced; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D009220:Myositis / Q000139:chemically induced*; D010396:Penicillamine / Q000009:adverse effects* / Q000627:therapeutic use; D012217:Rheumatoid Factor / Q000032:analysis; D013950:Thymus Gland / Q000187:drug effects / Q000276:immunology
D000906:Antibodies; D000974:Antibodies, Antinuclear; D007070:Immunoglobulin A; D007075:Immunoglobulin M; D003094:Collagen; D012217:Rheumatoid Factor; D010396:Penicillamine; D003348:Cortisone
Penicillamin-induzierte Polymyositis